Bristol-Myers Squibb to Buy Celgene, Combining Two Cancer-Drug Leaders


Bristol-Myers Squibb agreed to acquire Celgene for about $74 billion, creating a cancer-drug powerhouse, but one with questions about its long-term prospects.